{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T10:07:22Z","timestamp":1789726042363,"version":"4.0.1"},"reference-count":104,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["kidney-international.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney International"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.kint.2026.04.047","type":"journal-article","created":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T15:39:50Z","timestamp":1785166790000},"page":"841-850","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Secondary thrombotic microangiopathy in children\u2014a central role for the glycocalyx"],"prefix":"10.1016","volume":"110","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4242-3154","authenticated-orcid":false,"given":"Alison Lap-tak","family":"Ma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Alconcher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula","family":"Coccia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jack Wing-tak","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3831-1440","authenticated-orcid":false,"given":"Kristina","family":"Kusche-Vihrog","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4168-3277","authenticated-orcid":false,"given":"Christoph","family":"Licht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.kint.2026.04.047_bib1","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s00467-015-3076-8","article-title":"An international consensus approach to the management of atypical hemolytic uremic syndrome in children","volume":"31","author":"Loirat","year":"2016","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.kint.2026.04.047_bib2","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1056\/NEJMra1312353","article-title":"Syndromes of thrombotic microangiopathy","volume":"371","author":"George","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.kint.2026.04.047_bib3","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.kint.2024.05.021","article-title":"An expert discussion on the atypical hemolytic uremic syndrome nomenclature\u2014identifying a road map to precision: a report of a National Kidney Foundation Working Group","volume":"106","author":"Nester","year":"2024","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2026.04.047_bib4","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1016\/j.kint.2019.01.043","article-title":"Secondary atypical hemolytic uremic syndromes in the era of complement blockade","volume":"95","author":"Praga","year":"2019","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2026.04.047_bib5","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1016\/j.kint.2024.09.012","article-title":"Outcomes from the International Society of Nephrology Hemolytic Uremic Syndromes International Forum","volume":"106","author":"Kavanagh","year":"2024","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2026.04.047_bib6","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.kint.2019.08.001","article-title":"Complement inhibitors are not useful in secondary hemolytic uremic syndromes","volume":"96","author":"Duineveld","year":"2019","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2026.04.047_bib7","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1007\/s00467-021-05370-8","article-title":"Thrombotic microangiopathy in children","volume":"37","author":"Palma","year":"2022","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.kint.2026.04.047_bib8","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1182\/blood.2022018833","article-title":"Atypical hemolytic uremic syndrome in the era of terminal complement inhibition: an observational cohort study","volume":"142","author":"Brocklebank","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.kint.2026.04.047_bib9","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1007\/s00134-018-5059-2","article-title":"Understanding thrombotic microangiopathies in children","volume":"44","author":"Joly","year":"2018","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.kint.2026.04.047_bib10","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1007\/s00467-016-3399-0","article-title":"Renal thrombotic microangiopathy in patients with cblC defect: review of an under-recognized entity","volume":"32","author":"Beck","year":"2017","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.kint.2026.04.047_bib11","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/ng.2590","article-title":"Recessive mutations in DGKE cause atypical hemolytic-uremic syndrome","volume":"45","author":"Lemaire","year":"2013","journal-title":"Nat Genet"},{"key":"10.1016\/j.kint.2026.04.047_bib12","doi-asserted-by":"crossref","first-page":"881","DOI":"10.2215\/CJN.0000000000000182","article-title":"Epidemiology, outcomes, and complement gene variants in secondary thrombotic microangiopathies","volume":"18","author":"Werion","year":"2023","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2026.04.047_bib13","doi-asserted-by":"crossref","first-page":"557","DOI":"10.2215\/CJN.11470918","article-title":"Etiology and outcomes of thrombotic microangiopathies","volume":"14","author":"Bayer","year":"2019","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2026.04.047_bib14","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1016\/j.kint.2019.01.023","article-title":"Atypical and secondary hemolytic uremic syndromes have a distinct presentation and no common genetic risk factors","volume":"95","author":"Le Clech","year":"2019","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2026.04.047_bib15","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1093\/ndt\/gfaf091","article-title":"Complement activation in secondary thrombotic microangiopathies","volume":"40","author":"Morelle","year":"2025","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kint.2026.04.047_bib16","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.semnephrol.2013.08.003","article-title":"Atypical hemolytic uremic syndrome","volume":"33","author":"Kavanagh","year":"2013","journal-title":"Semin Nephrol"},{"key":"10.1016\/j.kint.2026.04.047_bib17","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.molimm.2015.06.021","article-title":"Complement factor H, FHR-3 and FHR-1 variants associate in an extended haplotype conferring increased risk of atypical hemolytic uremic syndrome","volume":"67","author":"Bernab\u00e9u-Herrero","year":"2015","journal-title":"Mol Immunol"},{"key":"10.1016\/j.kint.2026.04.047_bib18","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.2215\/CJN.02210310","article-title":"Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype","volume":"5","author":"Noris","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2026.04.047_bib19","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ekir.2020.10.009","article-title":"Complement in secondary thrombotic microangiopathy","volume":"6","author":"Palma","year":"2021","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.kint.2026.04.047_bib20","doi-asserted-by":"crossref","first-page":"300","DOI":"10.2215\/CJN.00620117","article-title":"Thrombotic microangiopathy and the kidney","volume":"13","author":"Brocklebank","year":"2018","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2026.04.047_bib21","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1055\/s-0034-1376153","article-title":"Spectrum of complement-mediated thrombotic microangiopathies: pathogenetic insights identifying novel treatment approaches","volume":"40","author":"Riedl","year":"2014","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.kint.2026.04.047_bib22","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1182\/blood-2014-02-558296","article-title":"Dynamics of complement activation in aHUS and how to monitor eculizumab therapy","volume":"124","author":"Noris","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.kint.2026.04.047_bib23","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1053\/j.ajkd.2018.11.012","article-title":"An ex vivo test of complement activation on endothelium for individualized eculizumab therapy in hemolytic uremic syndrome","volume":"74","author":"Galbusera","year":"2019","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.kint.2026.04.047_bib24","doi-asserted-by":"crossref","first-page":"2234","DOI":"10.1681\/ASN.2018020184","article-title":"C5b9 formation on endothelial cells reflects complement defects among patients with renal thrombotic microangiopathy and severe hypertension","volume":"29","author":"Timmermans","year":"2018","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2026.04.047_bib25","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1016\/j.ekir.2021.01.034","article-title":"Functional and genetic landscape of complement dysregulation along the spectrum of thrombotic microangiopathy and its potential implications on clinical outcomes","volume":"6","author":"Timmermans","year":"2021","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.kint.2026.04.047_bib26","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.ejim.2012.12.016","article-title":"The endothelial glycocalyx as a potential modifier of the hemolytic uremic syndrome","volume":"24","author":"Boels","year":"2013","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.kint.2026.04.047_bib27","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/s41581-018-0098-z","article-title":"Endothelium structure and function in kidney health and disease","volume":"15","author":"Jourde-Chiche","year":"2019","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.kint.2026.04.047_bib28","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2022.897087","article-title":"The endothelial glycocalyx: a possible therapeutic target in cardiovascular disorders","volume":"9","author":"Milusev","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.kint.2026.04.047_bib29","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.kint.2023.03.039","article-title":"Hemolysis is associated with altered heparan sulfate of the endothelial glycocalyx and with local complement activation in thrombotic microangiopathies","volume":"104","author":"Laboux","year":"2023","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2026.04.047_bib30","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s13054-018-2292-6","article-title":"The glycocalyx: a novel diagnostic and therapeutic target in sepsis","volume":"23","author":"Uchimido","year":"2019","journal-title":"Crit Care"},{"key":"10.1016\/j.kint.2026.04.047_bib31","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/S1357-2725(99)00116-8","article-title":"Heparan sulfate proteoglycans on the cell surface: versatile coordinators of cellular functions","volume":"32","author":"Tumova","year":"2000","journal-title":"Int J Biochem Cell Biol"},{"key":"10.1016\/j.kint.2026.04.047_bib32","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/nsmb.2018","article-title":"Structural basis for engagement by complement factor H of C3b on a self surface","volume":"18","author":"Morgan","year":"2011","journal-title":"Nat Struct Mol Biol"},{"key":"10.1016\/j.kint.2026.04.047_bib33","doi-asserted-by":"crossref","first-page":"126","DOI":"10.3389\/fimmu.2014.00126","article-title":"Molecular Interactions between complement factor H and its heparin and heparan sulfate ligands","volume":"5","author":"Perkins","year":"2014","journal-title":"Front Immunol"},{"key":"10.1016\/j.kint.2026.04.047_bib34","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1426526","article-title":"Dysregulated complement activation during acute myocardial infarction leads to endothelial glycocalyx degradation and endothelial dysfunction via the C5a:C5a-Receptor1 axis","volume":"15","author":"Vahldieck","year":"2024","journal-title":"Front Immunol"},{"key":"10.1016\/j.kint.2026.04.047_bib35","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/j.ajpath.2019.06.017","article-title":"Glycocalyx in endotoxemia and sepsis","volume":"190","author":"Goligorsky","year":"2020","journal-title":"Am J Pathol"},{"key":"10.1016\/j.kint.2026.04.047_bib36","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.ajpath.2022.12.009","article-title":"Endothelial glycocalyx and cardiomyocyte damage is prevented by recombinant syndecan-1 in acute myocardial infarction","volume":"193","author":"Vahldieck","year":"2023","journal-title":"Am J Pathol"},{"key":"10.1016\/j.kint.2026.04.047_bib37","article-title":"The loss of glycocalyx integrity impairs complement factor H binding and contributes to cyclosporine-induced endothelial cell injury","volume":"10","author":"Teoh","year":"2023","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.kint.2026.04.047_bib38","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1007\/s00795-022-00347-4","article-title":"Gemcitabine alters sialic acid binding of the glycocalyx and induces inflammatory cytokine production in cultured endothelial cells","volume":"56","author":"Gunji","year":"2023","journal-title":"Med Mol Morphol"},{"key":"10.1016\/j.kint.2026.04.047_bib39","doi-asserted-by":"crossref","first-page":"F454","DOI":"10.1152\/ajprenal.00376.2017","article-title":"Advances in our understanding of the pathogenesis of hemolytic uremic syndromes","volume":"314","author":"Bowen","year":"2018","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.kint.2026.04.047_bib40","doi-asserted-by":"crossref","first-page":"3133","DOI":"10.1038\/s41598-021-81847-8","article-title":"Effect of gestational age and postnatal age on the endothelial glycocalyx in neonates","volume":"11","author":"Puchwein-Schwepcke","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.kint.2026.04.047_bib41","doi-asserted-by":"crossref","DOI":"10.1016\/j.mbplus.2022.100106","article-title":"The endothelial glycocalyx in critical illness: a pediatric perspective","volume":"14","author":"Richter","year":"2022","journal-title":"Matrix Biol Plus"},{"key":"10.1016\/j.kint.2026.04.047_bib42","doi-asserted-by":"crossref","first-page":"H531","DOI":"10.1152\/ajpheart.00104.2018","article-title":"Advanced age results in a diminished endothelial glycocalyx","volume":"315","author":"Machin","year":"2018","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1016\/j.kint.2026.04.047_bib43","doi-asserted-by":"crossref","DOI":"10.3390\/ijms231810659","article-title":"Effects of chronic kidney disease on nanomechanics of the endothelial glycocalyx are mediated by the mineralocorticoid receptor","volume":"23","author":"Fels","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.kint.2026.04.047_bib44","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1007\/s00467-007-0518-y","article-title":"Streptococcus pneumoniae-associated hemolytic uremic syndrome","volume":"23","author":"Copelovitch","year":"2008","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.kint.2026.04.047_bib45","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1007\/s00467-019-04342-3","article-title":"New insights into the pathogenesis of Streptococcus pneumoniae-associated hemolytic uremic syndrome","volume":"35","author":"Scobell","year":"2020","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.kint.2026.04.047_bib46","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1542\/peds.101.4.699","article-title":"Hemolytic uremic syndrome associated with invasive Streptococcus pneumoniae infection","volume":"101","author":"Cabrera","year":"1998","journal-title":"Pediatrics"},{"key":"10.1016\/j.kint.2026.04.047_bib47","doi-asserted-by":"crossref","first-page":"7138","DOI":"10.1016\/j.vaccine.2020.08.068","article-title":"Ten year public health impact of 13-valent pneumococcal conjugate vaccination in infants: a modelling analysis","volume":"38","author":"Chapman","year":"2020","journal-title":"Vaccine"},{"key":"10.1016\/j.kint.2026.04.047_bib48","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.3390\/vaccines12101197","article-title":"Burden of pneumococcal disease in young children due to serotypes contained in different pneumococcal conjugate vaccines in eight Asian countries and territories","volume":"12","author":"Huang","year":"2024","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.kint.2026.04.047_bib49","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1093\/pch\/pxae055","article-title":"Streptococcus pneumoniae-associated hemolytic uremic syndrome Canadian Immunization Monitoring Program ACTive National Pediatric Surveillance (1991 to 2019)","volume":"30","author":"Lee","year":"2024","journal-title":"Paediatr Child Health"},{"key":"10.1016\/j.kint.2026.04.047_bib50","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1093\/cid\/ciy842","article-title":"Invasive pneumococcal disease in UK children <1 year of age in the post-13-valent pneumococcal conjugate vaccine era: what are the risks now?","volume":"69","author":"Kent","year":"2019","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.kint.2026.04.047_bib51","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1159\/000045396","article-title":"Positive Coombs test in pneumococcus-associated hemolytic uremic syndrome. A review of the literature","volume":"82","author":"von Vigier","year":"1999","journal-title":"Nephron"},{"key":"10.1016\/j.kint.2026.04.047_bib52","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1093\/infdis\/jix305","article-title":"Streptococcus pneumoniae from patients with hemolytic uremic syndrome binds human plasminogen via the surface protein PspC and uses plasmin to damage human endothelial cells","volume":"217","author":"Meinel","year":"2018","journal-title":"J Infect Dis"},{"key":"10.1016\/j.kint.2026.04.047_bib53","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1016\/S0140-6736(77)92915-4","article-title":"Thomsen-Friedenreich antigen in haemolytic-uraemic syndrome","volume":"2","author":"Klein","year":"1977","journal-title":"Lancet"},{"key":"10.1016\/j.kint.2026.04.047_bib54","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1007\/s00467-021-04952-w","article-title":"Complement activation in children with Streptococcus pneumoniae associated hemolytic uremic syndrome","volume":"36","author":"Holle","year":"2021","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.kint.2026.04.047_bib55","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1016\/j.ijmm.2018.08.007","article-title":"Complement depletion and Coombs positivity in pneumococcal hemolytic uremic syndrome (pnHUS). Case series and plea to revisit an old pathogenetic concept","volume":"308","author":"Bitzan","year":"2018","journal-title":"Int J Med Microbiol"},{"key":"10.1016\/j.kint.2026.04.047_bib56","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1093\/ndt\/gft198","article-title":"The role of complement in Streptococcus pneumoniae-associated haemolytic uraemic syndrome","volume":"28","author":"Szil\u00e1gyi","year":"2013","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kint.2026.04.047_bib57","article-title":"The pneumococcal surface proteins PspA and PspC sequester host c4-binding protein to inactivate complement C4b on the bacterial surface","volume":"87","author":"Haleem Kashif","year":"2018","journal-title":"Infect Immun"},{"key":"10.1016\/j.kint.2026.04.047_bib58","doi-asserted-by":"crossref","first-page":"224","DOI":"10.3389\/fmicb.2017.00224","article-title":"Role of Streptococcus pneumoniae proteins in evasion of complement-mediated immunity","volume":"8","author":"Andre","year":"2017","journal-title":"Front Microbiol"},{"key":"10.1016\/j.kint.2026.04.047_bib59","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.mehy.2013.05.030","article-title":"Does dysregulated complement activation contribute to haemolytic uraemic syndrome secondary to Streptococcus pneumoniae?","volume":"81","author":"Gilbert","year":"2013","journal-title":"Medical Hypotheses"},{"key":"10.1016\/j.kint.2026.04.047_bib60","doi-asserted-by":"crossref","first-page":"5319","DOI":"10.1128\/IAI.00543-06","article-title":"The contribution of PspC to pneumococcal virulence varies between strains and is accomplished by both complement evasion and complement-independent mechanisms","volume":"74","author":"Kerr","year":"2006","journal-title":"Infect Immun"},{"key":"10.1016\/j.kint.2026.04.047_bib61","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.28589","article-title":"Early initiation of eculizumab therapy for Streptococcus pneumoniae\u2013associated hemolytic uremic syndrome","volume":"68","author":"See","year":"2021","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.kint.2026.04.047_bib62","doi-asserted-by":"crossref","first-page":"4209","DOI":"10.1007\/s00467-023-06037-2","article-title":"Eculizumab use in patients with pneumococcal-associated hemolytic uremic syndrome and kidney outcomes","volume":"38","author":"Konop\u00e1sek","year":"2023","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.kint.2026.04.047_bib63","doi-asserted-by":"crossref","first-page":"2811","DOI":"10.1007\/s00467-021-04988-y","article-title":"Hemolytic uremic syndrome associated with Shiga toxin-producing Escherichia coli infection in Argentina: update of serotypes and genotypes and their relationship with severity of the disease","volume":"36","author":"Alconcher","year":"2021","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.kint.2026.04.047_bib64","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1056\/NEJMra2108739","article-title":"Shiga toxin-producing Escherichia coli and the hemolytic-uremic syndrome","volume":"389","author":"Freedman","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.kint.2026.04.047_bib65","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1007\/s00467-008-0935-6","article-title":"Treatment and outcome of Shiga-toxin-associated hemolytic uremic syndrome (HUS)","volume":"23","author":"Scheiring","year":"2008","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.kint.2026.04.047_bib66","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/s00467-024-06366-w","article-title":"Dynamic evolution of kidney function in patients with STEC-hemolytic uremic syndrome followed for more than 15 years: unexpected changes","volume":"40","author":"Alconcher","year":"2025","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.kint.2026.04.047_bib67","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1038\/nrneph.2012.196","article-title":"Renal and neurological involvement in typical Shiga toxin-associated HUS","volume":"8","author":"Trachtman","year":"2012","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.kint.2026.04.047_bib68","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1007\/s00467-024-06640-x","article-title":"Long-term health outcomes of Shiga toxin-producing Escherichia coli O157 (STEC O157) infection and STEC-associated haemolytic uraemic syndrome (STEC-HUS), Wales, 1990\u20132020","volume":"40","author":"Merrick","year":"2025","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.kint.2026.04.047_bib69","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1007\/s00467-023-06183-7","article-title":"Kidney sequelae in 281 Shiga toxin-producing Escherichia coli-hemolytic uremic syndrome patients after a median follow-up of 12 years","volume":"39","author":"Alconcher","year":"2024","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.kint.2026.04.047_bib70","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1007\/s00467-024-06355-z","article-title":"Outcome 10 years after Shiga toxin-producing E. coli (STEC)-associated hemolytic uremic syndrome: importance of long-term follow-up","volume":"39","author":"Rosales","year":"2024","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.kint.2026.04.047_bib71","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1093\/cid\/cix218","article-title":"Intermediate follow-up of pediatric patients with hemolytic uremic syndrome during the 2011 outbreak caused by E. coli O104:H4","volume":"64","author":"Loos","year":"2017","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.kint.2026.04.047_bib72","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1007\/s00467-018-3991-6","article-title":"Hyponatremia: a new predictor of mortality in patients with Shiga toxin-producing Escherichia coli hemolytic uremic syndrome","volume":"33","author":"Alconcher","year":"2018","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.kint.2026.04.047_bib73","doi-asserted-by":"crossref","first-page":"3777","DOI":"10.1007\/s00467-021-05108-6","article-title":"Hemoconcentration and predictors in Shiga toxin-producing E. coli-hemolytic uremic syndrome (STEC-HUS)","volume":"36","author":"Loos","year":"2021","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.kint.2026.04.047_bib74","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1007\/s00467-020-04717-x","article-title":"C3 levels and neurologic involvement in hemolytic uremic syndrome related to Shiga toxin-producing Escherichia coli","volume":"35","author":"Balestracci","year":"2020","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.kint.2026.04.047_bib75","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1016\/S0140-6736(73)92782-7","article-title":"Letter: serum-complement levels in haemolytic-uraemic syndrome","volume":"2","author":"Kaplan","year":"1973","journal-title":"Lancet"},{"key":"10.1016\/j.kint.2026.04.047_bib76","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.2215\/CJN.02730409","article-title":"Alternative pathway of complement in children with diarrhea-associated hemolytic uremic syndrome","volume":"4","author":"Thurman","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2026.04.047_bib77","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/s00467-016-3496-0","article-title":"Serological and genetic complement alterations in infection-induced and complement-mediated hemolytic uremic syndrome","volume":"32","author":"Westra","year":"2017","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.kint.2026.04.047_bib78","doi-asserted-by":"crossref","first-page":"6394","DOI":"10.4049\/jimmunol.0900151","article-title":"Shiga toxin activates complement and binds factor H: evidence for an active role of complement in hemolytic uremic syndrome","volume":"182","author":"Orth","year":"2009","journal-title":"J Immunol"},{"key":"10.1016\/j.kint.2026.04.047_bib79","doi-asserted-by":"crossref","first-page":"172","DOI":"10.4049\/jimmunol.1100491","article-title":"Alternative pathway activation of complement by Shiga toxin promotes exuberant C3a formation that triggers microvascular thrombosis","volume":"187","author":"Morigi","year":"2011","journal-title":"J Immunol"},{"key":"10.1016\/j.kint.2026.04.047_bib80","doi-asserted-by":"crossref","first-page":"5503","DOI":"10.1182\/blood-2010-09-309161","article-title":"Complement activation on platelet-leukocyte complexes and microparticles in enterohemorrhagic Escherichia coli-induced hemolytic uremic syndrome","volume":"117","author":"St\u00e5hl","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.kint.2026.04.047_bib81","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/j.medj.2023.09.002","article-title":"Shiga toxin targets the podocyte causing hemolytic uremic syndrome through endothelial complement activation","volume":"4","author":"Bowen","year":"2023","journal-title":"Med"},{"key":"10.1016\/j.kint.2026.04.047_bib82","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1056\/NEJMc1100859","article-title":"Eculizumab in severe Shiga-toxin\u2013associated HUS","volume":"364","author":"Lapeyraque","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.kint.2026.04.047_bib83","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.3201\/eid2707.204638","article-title":"Shiga toxin-associated hemolytic uremic syndrome in adults, France, 2009-2017","volume":"27","author":"Travert","year":"2021","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.kint.2026.04.047_bib84","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1681\/ASN.0000000000000182","article-title":"Efficacy and safety of eculizumab in pediatric patients affected by Shiga toxin-related hemolytic and uremic syndrome: a randomized, placebo-controlled trial","volume":"34","author":"Garnier","year":"2023","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2026.04.047_bib85","series-title":"Efficacy and mechanism evaluation. Efficacy and safety of eculizumab in children with Shiga-toxin-producing Escherichia coli haemolytic uraemic syndrome: the ECUSTEC RCT","author":"Ives","year":"2024"},{"key":"10.1016\/j.kint.2026.04.047_bib86","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s00467-023-05974-2","article-title":"Therapeutic drug monitoring in childhood idiopathic nephrotic syndrome: a state of the art review","volume":"39","author":"Lai","year":"2024","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.kint.2026.04.047_bib87","doi-asserted-by":"crossref","first-page":"3265","DOI":"10.1016\/j.ekir.2024.08.025","article-title":"Age-related differences in rejection rates, infections, and tacrolimus exposure in pediatric kidney transplant recipients in the CERTAIN registry","volume":"9","author":"Baghai Arassi","year":"2024","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.kint.2026.04.047_bib88","doi-asserted-by":"crossref","first-page":"481","DOI":"10.2215\/CJN.04800908","article-title":"Calcineurin inhibitor nephrotoxicity","volume":"4","author":"Naesens","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2026.04.047_bib89","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1093\/ndt\/gfg516","article-title":"Cyclosporin A toxicity, and more: vascular endothelial growth factor (VEGF) steps forward","volume":"19","author":"Caramelo","year":"2004","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kint.2026.04.047_bib90","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1681\/ASN.2012111064","article-title":"Cyclosporine induces endothelial cell release of complement-activating microparticles","volume":"24","author":"Renner","year":"2013","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2026.04.047_bib91","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.ekir.2018.11.010","article-title":"Eculizumab use for kidney transplantation in patients with a diagnosis of atypical hemolytic uremic syndrome","volume":"4","author":"Siedlecki","year":"2019","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.kint.2026.04.047_bib92","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1093\/ndt\/gfac248","article-title":"Thrombotic microangiopathy in patients with malignant hypertension","volume":"38","author":"Cavero","year":"2023","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kint.2026.04.047_bib93","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1097\/HJH.0000000000001913","article-title":"Malignant hypertension: diagnosis, treatment and prognosis with experience from the Bordeaux cohort","volume":"37","author":"Rubin","year":"2019","journal-title":"J Hypertens"},{"key":"10.1016\/j.kint.2026.04.047_bib94","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1161\/01.HYP.0000151620.17905.ee","article-title":"Microangiopathic hemolysis and renal failure in malignant hypertension","volume":"45","author":"van den Born","year":"2005","journal-title":"Hypertension"},{"key":"10.1016\/j.kint.2026.04.047_bib95","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1007\/s40620-022-01465-z","article-title":"Clinical characteristics and outcomes of a patient population with atypical hemolytic uremic syndrome and malignant hypertension: analysis from the Global aHUS registry","volume":"36","author":"Halimi","year":"2023","journal-title":"J Nephrol"},{"key":"10.1016\/j.kint.2026.04.047_bib96","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.kint.2025.09.033","article-title":"Severe hypertension with thrombotic microangiopathy: the need for pathogenically targeted treatments","volume":"109","author":"Praga","year":"2026","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2026.04.047_bib97","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1016\/j.kint.2016.12.009","article-title":"Patients with hypertension-associated thrombotic microangiopathy may present with complement abnormalities","volume":"91","author":"Timmermans","year":"2017","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2026.04.047_bib98","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.121.023397","article-title":"Malignant hypertension: current perspectives and challenges","volume":"11","author":"Boulestreau","year":"2022","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.kint.2026.04.047_bib99","doi-asserted-by":"crossref","first-page":"3048","DOI":"10.3390\/ijms21093048","article-title":"Can endothelial glycocalyx be a major morphological substrate in pre-eclampsia?","volume":"21","author":"Ziganshina","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.kint.2026.04.047_bib100","doi-asserted-by":"crossref","DOI":"10.1002\/cph4.70032","article-title":"Endothelial glycocalyx: the missing link between angiogenic imbalance in preeclampsia and systemic inflammation in HELLP syndrome","volume":"15","author":"Atallah","year":"2025","journal-title":"Compr Physiol"},{"key":"10.1016\/j.kint.2026.04.047_bib101","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/s41440-022-01061-5","article-title":"Nephrons, podocytes and chronic kidney disease: Strategic antihypertensive therapy for renoprotection","volume":"46","author":"Haruhara","year":"2023","journal-title":"Hypertens Res"},{"key":"10.1016\/j.kint.2026.04.047_bib102","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1016\/j.kint.2016.07.021","article-title":"Collapsing glomerulopathy is common in the setting of thrombotic microangiopathy of the native kidney","volume":"90","author":"Buob","year":"2016","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2026.04.047_bib103","doi-asserted-by":"crossref","DOI":"10.3389\/fped.2020.588911","article-title":"Hypertensive crisis in pediatric patients: an overview","volume":"8","author":"Raina","year":"2020","journal-title":"Front Pediatr"},{"key":"10.1016\/j.kint.2026.04.047_bib104","doi-asserted-by":"crossref","DOI":"10.1080\/0886022X.2024.2327484","article-title":"What came first, atypical hemolytic uremic syndrome or malignant hypertension: a clinical dilemma","volume":"46","author":"Sethi","year":"2024","journal-title":"Ren Fail"}],"container-title":["Kidney International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253826006162?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253826006162?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T09:30:29Z","timestamp":1789723829000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0085253826006162"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":104,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S0085253826006162"],"URL":"https:\/\/doi.org\/10.1016\/j.kint.2026.04.047","relation":{},"ISSN":["0085-2538"],"issn-type":[{"value":"0085-2538","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Secondary thrombotic microangiopathy in children\u2014a central role for the glycocalyx","name":"articletitle","label":"Article Title"},{"value":"Kidney International","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.kint.2026.04.047","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 International Society of Nephrology. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}